Introduction: Despite the growing interest in circulating cell-free DNA (cfDNA), no conclusive evidence exists on the value of quantitative analysis of cfDNA for the prediction of lung cancer survival. We performed a systematic review and meta-analysis of primary studies to estimate the impact of higher baseline cfDNA levels on survival outcomes of patients with lung cancer.
Introduction
Lung cancer is the leading cause of cancer-related death in the world, with more than 1 million deaths annually.
1 NSCLC and small cell lung cancer (SCLC) represent the two major histologies, the former accounting for approximately 85% of all diagnosed lung malignancies. 2 Despite a deeper understanding on the biology of lung cancer and the introduction of innovative therapeutic agents, the overall prognosis remains poor, with an average 5-year survival of approximately 15%. Late diagnosis still represents about 80% of cases.
Raised levels of circulating cell-free DNA (cfDNA) in cancer patients were first reported in 1977 by Leon et al. 5 and have now been reported in many cancer types, including lung cancer. 6 Although the precise mechanism of DNA release into the blood has not been fully elucidated, it is clear that much of it is derived from apoptotic and necrotic tumor cells. 7 Given that circulating DNA as a biomarker is easily accessible, reliable, and detectable early in the disease course, 8 quantitative detection of cfDNA, in either plasma or serum, has been proposed in lung cancer patients as a promising tool for diagnostic purposes. [9] [10] [11] The value of quantitative analysis of cfDNA as a screening tool for lung cancer has been recently summarized by a meta-analysis that found a diagnostic accuracy not lower than conventional circulating biomarkers for lung cancer screening. 12 Several studies have also investigated the value of quantitative analysis of circulating cfDNA for survival prediction in cancer patients. However, contrasting results have been reported on the impact of higher baseline cfDNA levels on lung cancer survival, with some studies reporting an increased risk of death [13] [14] [15] and other authors failing to replicate this finding. 16, 17 Despite an increasing number of studies focusing on circulating cfDNA, no conclusive evidence exists on the value of quantitative analysis of cfDNA for prediction of lung cancer survival, and no meta-analysis has been conducted to clarify this issue. The aim of the present study was to fill this gap by performing a systematic review and meta-analysis of relevant studies to accurately estimate the impact of higher baseline cfDNA levels on survival outcomes of patients with lung cancer. Quality assessment of primary studies and the potential for publication bias were considered part of the metaanalytic process. In addition, subgroup and sensitivity analyses were conducted to explore possible explanations for heterogeneity and to examine the impact of potential confounders on the pooled estimates.
Materials and Methods

Search Strategy and Eligible Criteria
The protocol for this review was published in the PROSPERO database 18 of prospectively registered systematic reviews (database registration CRD42016035965). PubMed, Web of Knowledge, and Cochrane Library databases were searched up to March 2016 using the Boolean combination of the following key terms: lung cancer AND (survival or prognosis) AND (cellfree DNA OR circulating DNA or circulating-free DNA OR circulating cell free DNA OR cfDNA OR total circulating free DNA OR extracellular DNA). We searched for primary studies evaluating the impact of higher baseline levels of cfDNA on survival outcomes. Inclusion criteria were: 1) human studies focusing on lung cancer; 2) studies exploring the relation between baseline cfDNA levels and 1 or more of the following time to events outcomes: overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), or time to progression (TTP). Exclusion criteria were as follows: 1) reviews, meeting abstracts, case studies, and editorials; 2) not human studies; 3) circulating tumor cells; 4) qualitative analysis on circulating tumor DNA; 5) circulating RNA; and 6) microsatellite studies. There were no language restrictions. The retrieved studies were then read in their entirety to assess their appropriateness for inclusion. All references cited in the eligible studies were also reviewed to identify additional published works that were not initially retrieved. If 2 or more studies shared part of the same patient population, the more complete or the one with the larger sample size was included. If survival estimates were not reported or calculable from the original published data, corresponding authors were contacted via e-mail and studies were excluded if relevant data were not provided. All studies were independently analyzed by two reviewers (S.T. and S.C.), and any discrepancies in data extraction were resolved through consensus.
Data Extraction
A standardized form was used for each study from which the following information was extracted: the first author's last name, year of publication, study location, total number of enrolled lung cancer patients and those included in survival analysis, type of lung cancer and number of patients for each stage, treatment methods, DNA source, detection method, and cutoff threshold of baseline cfDNA levels. For each survival outcome reported, the hazard ratio (HR) as well as its 95% confidence interval (CI) was extracted from the study report where possible; otherwise, HRs and 95% CIs were estimated using the method described by Parmar et al. 19 or extrapolated from Kaplan-Meier curves by using KurvE software (Internovi di Scarpellini, Daniele SAS, Cesena, Italy). When HRs and 95% CIs were extracted from the Kaplan-Meier curve, we also attempted to check the results with the authors, because there is a potential to overestimate the true number of events. 20 When HR was adjusted for covariates, it was also extracted along details of the corresponding covariates (Table 1; Supplementary  Table 1 ). All studies have been independently analyzed by two reviewers (S.T. and S.C.), and any discrepancies have been resolved through consensus.
Study Quality
We assessed the quality of studies included in the systematic review by using the Newcastle-Ottawa scale (NOS) for nonrandomized studies (available at: http://www.ohri.ca/programs/clinical-epidemiology/ oxford-asp). The studies were judged on three major components: 1) selection of the groups of study (0-4 points), 2) comparability of cohorts (0-2 points), and 3) assessment of the outcome or exposure (0-3 points). The maximum score could be 9 points, representing the highest methodologic quality. Studies with a NOS score greater than 7 were considered of higher quality. Two reviewers (S.T. and S.C.) independently assessed the quality of each study, and disagreements were resolved through consensus.
Statistical Analysis
OS was defined as the primary survival outcome of interest, while PFS, TTP, or DFS were considered secondary outcomes. In order to conduct robust metaanalyses, we pooled survival outcomes that were reported in 3 independent studies. For each time to event outcome, adjusted HR was combined if these were available; otherwise, unadjusted estimates were used. Outcome estimates were pooled using the random effects (DerSimonian and Laird) model because it takes into account any difference among studies even if there is no statistical heterogeneity. 21 In case of lack of heterogeneity, the random effects model coincides with the fixed effect model. 22 We estimated the between-study heterogeneity across all eligible comparisons by using the c 2 -based Cochran's Q statistic (significant for p < 0.10). 23 We also reported the I 2 index (range 0-100%), which quantifies heterogeneity regardless of the number of studies. Where the I 2 estimate was 50% or more, we interpreted this as indicating the presence of high levels of heterogeneity. 24 Leave-one-out sensitive meta-analysis was performed to assess the contribution of each study to the pooled estimate by excluding individual results one at a time and recalculating the pooled OR estimates for the remaining results. To assess the robustness of overall findings and to further explore possible reasons for heterogeneity, subgroup and sensitivity analyses were conducted when relevant data were reported in at least three independent studies. The presence and extent of publication bias and small-study effects was evaluated graphically by drawing funnel plots for each outcome measure and statistically by means of Egger's standard regression test. 25 An Egger's test p value less than 0.10 was considered to indicate statistically significant publication bias. All pooled analyses were performed using ProMeta software (version 2; Internovi di Scarpellini, Daniele SAS, Cesena, Italy), and the significance of pooled estimates was set at p value less than 0.05.
Results
Characteristics of Identified Studies
The keywords used to search PubMed, Web of Knowledge, and Cochrane databases yielded 507 hits, and 153 were duplicates. By screening titles and abstracts, 254 records were then excluded and 100 potential studies remained available for full-text screening. After removal of 83 studies not fulfilling the inclusion criteria, 17 studies were finally included in the systematic review. [13] [14] [15] [16] [17] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] The detailed flowchart of the literature review process with reasons of study exclusion is shown in Figure 1 . The identified studies were published between 1995 and 2016, with sample sizes ranging from 22 to 446 lung cancer patients. Approximately one-third of the studies (6/17; 35.3%) included more than 100 patients in the survival analysis. 13, 14, 16, 17, 32, 37 Details on the demographic and clinical characteristics of the 17 studies are shown in Table 1 . Among them, 12 studies were conducted in Europe, [13] [14] [15] [26] [27] [28] [29] 31, [34] [35] [36] [37] three in East Asian countries, 16, 32, 33 one in north America, 17 and one in India. 30 All manuscripts were written in English with the exception of a manuscript in Spanish. 27 Sixteen studies included patients with NSCLC only, 13-17,27-37 most of which were at stage III/IV only, 14, 16, 17, 27, 30, [32] [33] [34] [35] 37 while one study 26 included both NSCLC and SCLC patients. Treatment methods included chemotherapy in 11 studies, [13] [14] [15] [16] [17] 27, 30, 32, 33, 35, 37 surgery in two, 28, 29 radiotherapy in one, 36 and different combinations of chemotherapy, radiotherapy, or surgery in three studies. 26, 31, 34 cfDNA was obtained from plasma in 15 studies, [14] [15] [16] [17] 26, [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] from serum in a single study, 27 and from both plasma and serum in one other study. 13 Among the different methods of cfDNA detection, quantitative real-time polymerase chain reaction (qPCR) was the most commonly used, being applied in 12 studies, [13] [14] [15] 17, 28, 29, [31] [32] [33] [34] [35] [36] of whom five by means of the human telomerase reverse transcriptase (hTERT) gene amplification. 14, 15, 28, 29, 36 HR estimate was reported in the text or provided by the corresponding author in 11 studies, [14] [15] [16] [17] 28, [32] [33] [34] [35] [36] [37] while it was extrapolated in six studies. 13, 26, 27, [29] [30] [31] HRs and 95% CIs for OS were obtained in 16 studies, [13] [14] [15] [16] [17] 26, [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] PFS in five, 16, 17, 32, 35, 37 DFS in two, 28, 36 and TTP in two studies. 14,27 Adjusted HRs were available in 8 studies. [13] [14] [15] [16] [32] [33] [34] [35] [36] [37] The quality of identified studies was evaluated according to NOS and results are shown in Table 2 . The quality score ranged from 6 to 8 (median 7). The seven studies 13, 14, 16, [32] [33] [34] 37 with NOS scores greater than 7 were considered of higher quality.
Quantitative Data Synthesis
A total of 16 studies [13] [14] [15] [16] [17] 26, [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] including 1723 patients with lung cancer were involved in the meta-analysis for the relationship between baseline levels of plasma cfDNA and OS ( Fig. 2A and Table 3 ). Despite significant heterogeneity among studies (p < 0.0001; I 2 ¼ 66%), the pooled HR showed an increased risk of death in patients with higher baseline cfDNA levels (HR 1.76 [95% CI 16 study was omitted. To further assess the robustness of overall findings and explore possible reasons for the observed heterogeneity, we conducted subgroup analyses including study location, source of HR estimate, method of survival analysis, cfDNA detection method, cutoff threshold of baseline cfDNA levels, sample size, and NOS score. As shown in Table 3 , significant between-study heterogeneity was detected across all comparisons, except among studies using tertile-or quartile-based cutting points of cfDNA levels (p ¼ 0. (Table 3) , despite nonsignificant heterogeneity detected only among studies assessing cfDNA by qPCR of hTERT gene amplification (p ¼ 0.345; I 2 ¼ 11). Similar conclusions were drawn when overall or subgroup analyses were restricted to studies recruiting only patients with NSCLC (Table 1; Supplementary Table 2) .
A total of five studies 16, 17, 32, 35, 37 including 640 patients with NSCLC were involved in the meta-analysis for the relationship between baseline levels of plasma cfDNA and PFS (Fig. 2B and Table 3 ). The pooled HR showed no association of baseline cfDNA with PFS (HR 1.12 [95% CI 0.91-1.37]; p ¼ 0.29) and no significant between-study heterogeneity (p ¼ 0.23; I 2 ¼ 28%). Nevertheless, leave-one-out sensitivity meta-analysis suggested lack of robustness of the overall result, given that a borderline significant association with PFS was detected after exclusion of Wang et al. 16 from the pooled analysis (HR 1.21 [95% CI 1.00-1.45]; p ¼ 0.049) (Fig. 1B and Supplementary Fig. 1 ). Meta-analyses for TTP 14, 27 and DFS 28, 36 were not performed because these outcomes were reported in fewer than 3 studies.
Publication Bias
Funnel plot and Egger's test were performed to evaluate publication bias for OS or PFS. The shape of HRs and 95% confidence intervals were provided by the corresponding author after being contacted. b2M, b2 microglobulin; DFS, disease-free survival; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HR, hazard ratio; hTERT, human telomerase reverse transcriptase; MV, multivariate analysis; OS, overall survival; PFS, progression-free survival; PPIA, peptidylprolyl isomerase A; RT, radiotherapy; qPCR, quantitative real-time polymerase chain reaction; RT, radiotherapy; SCLC, small cell lung cancer; TTP, time to tumor progression; UV, univariate analysis.
both funnel plots appeared approximately symmetrical ( Fig. 3A and B) , and the p values of Egger's test for OS and PFS were 0.199 and 0.642, respectively, suggesting no evidence for publication bias.
Discussion
The recent development of sensitive and accurate methods of detection and quantitative analysis of cfDNA has given rise to a growing interest in this field.
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Although the precise mechanism remains to be established, the finding that cfDNA mostly derives from lysis of necrotic and apoptotic tumor cells 7, 39 has provided the rationale for its use as a surrogate source of tumor DNA. In the last decade, a number of studies have been conducted to assess the value of quantitative analysis of cfDNA for the prediction of lung cancer survival, but the results have been so far inconclusive. In order to elucidate this issue and contribute to a broader discussion on the role of cfDNA as a biomarker, we conducted a systematic revision with meta-analysis of primary studies to estimate the impact of baseline cfDNA levels on survival outcomes of patients with lung cancer.
Our findings show for the first time evidence that increased baseline cfDNA levels in plasma of patients with lung cancer are associated with shorter OS, a result that supports clinical validity of cfDNA quantification for prediction of lung cancer survival. Although cutoff thresholds of plasma cfDNA varied widely across studies, our pooled analysis for OS is consistent with findings of the majority of included studies. The robustness of the pooled OS analysis was first tested by leave-one-out meta-analysis, which showed that no individual study had an excessive influence on the association with OS. Then, several subgroup and sensitivity analyses were conducted to explore possible explanations for the observed heterogeneity and to examine the impact of potential confounders on the pooled OS estimate. Despite substantial heterogeneity was still detected across most comparisons, these further analyses did not substantially alter the overall result of our analysis. It is worthy to note that lack of significant heterogeneity was detected only among studies that used the real-time qPCR based on the hTERT gene amplification (p ¼ 0.345; I 2 ¼ 11%), or among those using tertile-or quartile-based methods for cutoff determination (p ¼ 0.610; I 2 ¼ 0%). These observations raise the possibility that the technique used for cfDNA detection and the method of cutoff determination may be the main sources of the observed heterogeneity. In recent years, with the rapid development of PCR-based techniques, the methods used in early studies for detection and quantification of cfDNA levels have been gradually replaced by qPCR because of high accuracy, reproducibility, and time effectiveness. However, despite most of the identified studies determining cfDNA levels by qPCR, [13] [14] [15] 17, 28, 29, [31] [32] [33] [34] [35] [36] different reference genes were used, including hTERT, 14, 15, 28, 29, 36 glyceraldehyde 3-phosphate dehydrogenase, 13, 33 or b-actin 17, 32 and a wide range of cutoff thresholds. Additional investigation is therefore warranted to establish a consensus on preanalytical and analytical protocols for cfDNA analysis 40, 41 and the optimal cutoff values for patients' stratification. On the other hand, it should be noted that the association with OS failed to reach statistical significance in studies not using qPCR 16, 26, 30, 37 or that considered only East Asian populations. 16, 30, 32, 33 However, we cannot exclude that these results may be related to the limited number of patients included in these analyses. The same conclusion could be drawn for the nonsignificant association of plasma cfDNA with PFS, for which additional studies are still needed to provide conclusive evidence of a relationship.
Our findings should be interpreted in light of the following limitations and considerations. First, substantial between-study heterogeneity was found in the meta-analysis of OS. This is probably explained by the lack of standardization of the cfDNA test, with major differences regarding method of quantification and cutoff thresholds. Despite these two aspects being identified as potential explanatory variables, other factors could also explain the observed between-study heterogeneity. For instance, circulating cfDNA levels may reflect not only changes in circulating tumor DNA but also reflect medical conditions or patient characteristics that may lead to an increase in cfDNA concentration. 42 Second, about two-thirds of the identified studies involved less than 100 patients with lung cancer in the survival analysis; caution is needed in the interpretation of the pooled HR estimates. In this regard, alternative approaches to the classical random effects meta-analysis, such as bootstrapping or its Bayesian analogue, may be used in order to provide more robust estimates and CIs. Third, although we attempted to contact the corresponding authors of potentially relevant papers, some of them were unavailable to provide data requested for inclusion in the meta-analysis and this might have affected the results. In addition, we could not evaluate the impact of baseline cfDNA levels on survival and objective response rate after specific cancer treatments because of an extreme intra-and interstudy heterogeneity in terms of chemotherapy drugs and regimens. In summary, the current meta-analysis shows for the first time evidence of an increased risk of death in patients with lung cancer who have higher baseline cfDNA levels, thereby supporting clinical validity of quantitative analysis of cfDNA for prediction of lung cancer survival. Nevertheless, the establishment of a robust, well standardized method for detection and quantification of cfDNA and determination of the optimal cutoff thresholds are still required to define the clinical relevance of cfDNA quantification for lung cancer management.
